JP Morgan Chase
CTSO icon

JP Morgan Chase’s Cytosorbents Corp CTSO Stock Holding History

JP Morgan Chase’s Portfolio CTSO Stock Details CTSO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$208 Hold
372
– – ﹤0.01% 7248
2025
Q4 		$238 Hold
372
– – ﹤0.01% 7143
2025
Q3 		$347 Hold
372
– – ﹤0.01% 7078
2025
Q2 		$476 Sell
372
-113
-23% -$113 ﹤0.01% 6701
2025
Q1 		$485 Sell
485
-9
-2% -$9 ﹤0.01% 6707
2024
Q4 		$450 Buy
494
+122
+33% +$120 ﹤0.01% 6814
2024
Q3 		$558 Hold
372
– – ﹤0.01% 6791
2024
Q2 		$262 Hold
372
– – ﹤0.01% 6751
2024
Q1 		$353 Hold
372
– – ﹤0.01% 6756
2023
Q4 		$413 Hold
372
– – ﹤0.01% 6953
2023
Q3 		$699 Hold
372
– – ﹤0.01% 6685
2023
Q2 		$1.33K Hold
372
– – ﹤0.01% 6416
2023
Q1 		$1K Hold
372
– – ﹤0.01% 6508
2022
Q4 		$1K Hold
372
– – ﹤0.01% 6391
2022
Q3 		$1K Sell
372
-26,441
-99% -$51.6K ﹤0.01% 6307
2022
Q2 		$59K Buy
26,813
+7,102
+36% +$16.3K ﹤0.01% 5608
2022
Q1 		$63K Sell
19,711
-52,675
-73% -$189K ﹤0.01% 5705
2021
Q4 		$304K Buy
72,386
+56,784
+364% +$319K ﹤0.01% 5125
2021
Q3 		$126K Sell
15,602
-502
-3% -$4.08K ﹤0.01% 5455
2021
Q2 		$122K Buy
16,104
+428
+3% +$3.61K ﹤0.01% 5472
2021
Q1 		$136K Sell
15,676
-2,520
-14% -$24K ﹤0.01% 5297
2020
Q4 		$145K Buy
18,196
+2,883
+19% +$24.1K ﹤0.01% 4907
2020
Q3 		$124K Buy
15,313
+3,715
+32% +$33.5K ﹤0.01% 4594
2020
Q2 		$115K Buy
11,598
+1,816
+19% +$16.7K ﹤0.01% 4507
2020
Q1 		$76K Sell
9,782
-30,470
-76% -$154K ﹤0.01% 4599
2019
Q4 		$155K Buy
40,252
+30,214
+301% +$132K ﹤0.01% 4763
2019
Q3 		$50K Buy
10,038
+1,628
+19% +$9.47K ﹤0.01% 5176
2019
Q2 		$56K Buy
8,410
+1,154
+16% +$7.93K ﹤0.01% 5125
2019
Q1 		$55K Sell
7,256
-2,825
-28% -$22K ﹤0.01% 5093
2018
Q4 		$81K Sell
10,081
-88,107
-90% -$875K ﹤0.01% 4924
2018
Q3 		$1.27M Sell
98,188
-99,392
-50% -$1.25M ﹤0.01% 3766
2018
Q2 		$2.25M Buy
+197,580
New +$1.87M ﹤0.01% 3326
2018
Q1 		– Sell
-6,000
Closed -$39K – 5425
2017
Q4 		$39K Buy
6,000
+5,715
+2,005% +$36.4K ﹤0.01% 4966
2017
Q3 		$2K Hold
285
– – ﹤0.01% 4873
2017
Q2 		$1K Sell
285
-1,335
-82% -$5.85K ﹤0.01% 4874
2017
Q1 		$7K Sell
1,620
-381
-19% -$2.13K ﹤0.01% 4857
2016
Q4 		$11K Sell
2,001
-118
-6% -$646 ﹤0.01% 4782
2016
Q3 		$14K Buy
2,119
+77
+4% +$400 ﹤0.01% 4248
2016
Q2 		$9K Hold
2,042
– – ﹤0.01% 4353
2016
Q1 		$8K Sell
2,042
-469
-19% -$2.04K ﹤0.01% 4285
2015
Q4 		$14K Buy
+2,511
New +$17.1K ﹤0.01% 4140

Other funds holding CTSO

AC
Avenir Corporation Alexandria, Virginia $820M AUM 2.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SC
Skylands Capital Milwaukee, Wisconsin $763M AUM 26.49% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

JP Morgan Chase's CTSO Position: Q1 2026 in Review

JP Morgan Chase held its Cytosorbents Corp (CTSO) position steady in Q1 2026 at 372 shares worth $208. The position accounts for ﹤0.01% of the portfolio, ranked #7248.

JP Morgan Chase first reported a position in CTSO in Q4 2015 and has held it in 41 quarters since. The position peaked at $2.25M in Q2 2018. 50 funds tracked by Wall St. Rank hold CTSO as of Q1 2026.

  • JP Morgan Chase held 372 shares of Cytosorbents Corp worth $208 as of Q1 2026.
  • JP Morgan Chase left its Cytosorbents Corp share count unchanged in Q1 2026.
  • Cytosorbents Corp made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #7248 holding.
  • JP Morgan Chase first reported a position in Cytosorbents Corp in Q4 2015 and has held it in 41 quarters since.
  • JP Morgan Chase's Cytosorbents Corp position peaked at $2.25M in Q2 2018.
  • 50 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.